The power of syndromic testing for infectious diseases

Patients with infectious illnesses frequently have signs and symptoms that are indicative of a disease, but that are not specific enough to clinically distinguish what makes them ill.

Patients present with general symptoms such as cough, myalgia and headache. The lack of a clear diagnosis results in patients being given broad treatment, heavy monitoring and possibly unnecessary interventions.

Traditional diagnostic methodologies and technologies, such as bacterial culture and microscopy, take too long or are not sensitive enough. If a causative pathogen is eventually identified, too much time has been taken to make impactful clinical decisions. Can a patient presenting at the ER go home or is hospitalization required? Is an antibiotic or other treatment necessary? Does the patient need to be isolated?

Download our infographic to see how the benefits of syndromic testing go beyond improved patient care and extend throughout your hospital system.

Download infographic

QIAstat-Dx: the next generation of syndromic insights

Rapid syndromic testing with the QIAstat-Dx Analyzer helps eliminate the guesswork to answer these questions and facilitate clinically meaningful decision making. QIAstat-Dx strengthens the overall clinical assessment so that doctors and patients can receive a definitive diagnosis in about one hour, helping to support timely decisions about treatment, hospital admission, infection control, antimicrobial stewardship and outbreak tracking.

The size of a small printer, the QIAstat-Dx Analyzer provides simultaneous qualitative detection and identification of multiple respiratory viral and bacterial pathogens with one panel test, as opposed to multiple tests as traditionally performed. Less than one minute hands-on time is needed to prepare a sample, enabling answers fast and onsite, right where they’re needed. The QIAstat-Dx Analyzer runs with all-in-one cartridges that contain wet and dry reagents on-board and does not require precision pipetting, facilitating ease of use for lab technicians and nurses.

In addition, the QIAstat-Dx Analyzer can identify co-infections, providing valuable insights on sample quality. Several studies have demonstrated how using panels to detect multiple pathogens at once is associated with improvements in clinical practice and outcomes, from increased diagnostic yield and greater diagnostic accuracy to reduced use of resources, antibiotic use and overall length of stay.

The QIAstat-Dx Analyzer represents the next generation in multiplex molecular diagnostic systems that enables rapid, accurate and comprehensive syndromic testing with novel Sample to Insight solutions powered by QIAGEN chemistries. Powered by QIAstat-Dx, your lab will provide clinicians with the information they need to help confidently diagnose and guide therapy selection, improving patient care with rapid and accurate treatment.

The QIAstat-Dx Respiratory Panel is a true Sample to Insight solution for patients with suspected upper respiratory infections, detecting 20 viral and bacterial targets in about an hour. Some of the targets include adenovirus, enterovirus, metapneumovirus, coronavirus, influenza, respiratory syncytial virus A/B, parainfluenza, and B. pertussis.

The QIAstat-Dx Respiratory SARS-CoV-2 (Emergency Use Authorization)is the expanded version of our multiplex respiratory cartridge that detects 21 viral and bacterial respiratory targets, including SARS-CoV-2 to support efforts to provide accessible testing to meet the demands of the COVID-19 outbreak.

References:
1. Ramanan P., Bryson A.L., Binnicker M.J., Pritt B.S., Patel R. (2018) Syndromic panel-based testing in clinical microbiology. Clin Microbiol Rev. doi.org/10.1128/CMR.00024-17.

Be the first to know about QIAstat-Dx news and webinars

Send me updates
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
  • This test has not been FDA cleared or approved;
  • This test has been authorized by FDA under an EUA for use by authorized laboratories;
  • This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
  • Social Sharing